April twenty _ fifthRoobetcrashGuangzheng Ophthalmology (002524), an A-share listed company, released its annual report for 2023. Of which, the net profit is 925.Roobetcrash.500,000 yuan to turn losses into profits.

According to the comprehensive operation and follow-up analysis of more than 1200 financial indicators of its financial data in the current period and the past five years, according to the financial diagnosis model of flush (300033), the overall financial situation of orthopedic ophthalmology in the past five years is lower than the industry average. Specifically, the cash flow is good and the operating ability is excellent.

A net profit of 9.255 million yuan, turning a loss into a profit

In terms of revenue and profit, the company achieved a total operating income of 1.075 billion yuan in the reporting period, an increase of 40.06% over the same period last year, and a net profit of 9.255 million yuan. It lost 78.2176 million yuan in the same period last year, and basic earnings per share was 0.02 yuan.

In terms of assets, during the company's reporting period, the total assets at the end of the period were 1.549 billion yuan and accounts receivable were 119 million yuan; in terms of cash flow, the net cash flow generated by business activities was 38.906 million yuan, and the cash received by selling goods and providing services was 974 million yuan.

The financial situation is good, there are 5 financial bright spots

According to the relevant financial information released by Guangzheng Ophthalmology, there are five financial bright spots in the company, as follows:

The average turnover rate of accounts receivable is 11.30 (times / year), and the company collects accounts quickly. The average turnover rate of total operating assets is 0.69 (times / year), and the company has high operational efficiency. The average cash content of income and net profit is 332.82%, which is excellent in the industry. The revenue of the growth period increased by 40.06% compared with the same period last year, and the revenue growth performance was excellent. The net profit of the growth period increased by 111.83% compared with the same period last year, turning losses into profits.

There are two financial risks

According to the relevant financial information released by Guangzheng Ophthalmology, the company has two financial risks, as follows:

According to the type of indicators, the proportion of debt and interest-paying debt is 30.53%, and there is a great pressure on debt repayment. The liquidity ratio is 0.42, and the short-term solvency is very weak.

Overall, the overall financial situation of Guangzheng Ophthalmology is lower than the industry average, with a current total score of 1.70, ranking low among 52 companies in the medical service industry. Specifically, the cash flow is good and the operating ability is excellent.

The scores of the indicators are as follows:

Index type previous period score ranking evaluation operating ability 5.005.001 excellent cash flow 4.063.7514 good growth ability 0.092.6925 still available asset quality 2.262.5027 still profitability 0.660.8744 lower solvency 0.190.1052 lower total score 1.311.7041 lower than industry average

On the large model of financial diagnosis of flush

Flush (300033) Financial diagnosis model calculates the company's financial scores, highlights and risks based on the company's latest and previous financial data and industry conditions, reflecting the company's disclosed financial position, but not a forecast of the future financial position. The financial score range is 0-5. The higher the score, the better the financial situation and the greater the value of the medium-and long-term investment. In the financial highlights and risk reviews, the five-year average of the indicators related to the "average" keyword, and the latest reporting period data without the "average" keyword. All the above information is based on artificial intelligence algorithm, for reference only, does not represent flush financial point of view, investors operate accordingly, at their own risk.

Learn more about the company's stock diagnostic information >